Persistence of survivin specific T cells for seven years in a melanoma patient during complete remission

Cancer Biology and Therapy

Volumn 5, Issue 5, 2006, Pages 480-482

  Hadrup, Sine Reker ^a   Gehl, Julie ^b   Sørensen, Rikke Bæk ^a   Geertsen, Poul F ^b   Straten, Per Thor ^a   Andersen, Mads Hald ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CD8 T cells; ELISPOT0; Immunotherapy; Survivin; Tumor immunology

Indexed keywords

BLEOMYCIN; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2; SURVIVIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CD8+ T LYMPHOCYTE; ELECTROCHEMOTHERAPY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HLA SYSTEM; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; MELANOMA; METASTASIS; REMISSION;

EID: 33646788797     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.5.2652     Document Type: Article

References (19)

1. Otto K, Andersen MH, Eggert A, Keikavoussi P, Pedersen LO, Rath JC, et al. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 2005; 23:884-9.
2. Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2005; 1-5.
3. Andersen MH, Becker JC, thor Straten P. Regulators of apoptosis: Suitable targets for immune therapy of cancer. Nat Rev Drug Discov 2005; 4:399-409.
4. Robbins PF, Dudley ME, Wunderlich J, El Gamil M, Li YF, Zhou J, et al. Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004; 173:7125-30.
5. Huang J, Khong HT, Dudley ME, El Gamil M, Li YF, Rosenberg SA, et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J.Immunother 2005; 28:258-67.
6. Gothelf A, Mir LM, Gehl J. Electrochemotherapy: Results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003; 29:371-87.
7. Andersen MH, Gehl J, Reker S, Pedersen LO, Becker JC, Geertsen P, et al. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 2003; 13:449-59.
8. Scheibenbogen C, Lee KH, Mayer S, Stevanovic S, Moebius U, Herr W, et al. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res 1997; 3:221-6.
9. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985; 161:1169-88.
10. Mir LM, Roth C, Orlowski S, Quintin-Colonna F, Fradelizi D, Belehradek Jr J, et al. Systemic antitumor effects of electrochemotherapy combined with histoincompatible cells secreting interleukin-2. J Immunother Emphasis Tumor Immunol 1995; 17:30-8.
11. Reker S, Becker JC, Svane IM, Ralfkiaer E, thor Straten P, Andersen MH. HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer 2004; 108:937-41.
12. Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P, et al. Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther 2004; 3:173-9.
13. Andersen MH, Gehl J, Reker S, Pedersen LO, Becker JC, Geertsen P, et al. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 2003; 13:449-59.
14. McCutcheon M, Wehner N, Wensky A, Kushner M, Doan S, Hsiao L, et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods 1997; 210:149-66.
15. Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004; 113:1515-25.
16. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001; 61:5964-8.
17. Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J, et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 2000; 60:1815-7.
18. Yagihashi A, Asanuma K, Nakamura M, Araya J, Mano Y, Torigoe T, et al. Detection of anti-survivin antibody in gastrointestinal cancer patients. Clin Chem 2001; 47:1729-1731.
19. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 2004; 103:2046-54.